Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2019

Open Access 01-12-2019 | Prostate Cancer | Research

Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer

Authors: Yafang Zhang, Ping Li, Qi Yu, Shuang Wu, Xue Chen, Qing Zhang, Shen Fu

Published in: Radiation Oncology | Issue 1/2019

Login to get access

Abstract

Purpose

To assess toxicity and quality-of-life (QOL) after carbon ion radiotherapy (CIRT) at the Shanghai Proton and Heavy Ion Center (SPHIC) and identify clinical factors that correlate with urinary, bowel and sexual function.

Methods

Sixty-four patients with localized prostate cancer admitted from July 2015 to January 2018 underwent CIRT. At baseline and 5 time-points after radiotherapy, we assessed patients’ QOL using the 26-item edition of the Expanded Prostate Cancer Index-Composite (EPIC-26) Chinese version. Logistic regression was performed to identify clinical factors associated with acute genitourinary (GU) toxicity and relative QOL.

Results

By the end of CIRT, urinary irritation/obstruction temporarily declined (− 7.92 ± 1.76, p < .001). For urinary incontinence, bowel and sexual QOL, the scores remained stable at 2-year follow-up. The occurrences of acute Grade 1 and 2 GU toxicity were 20.3 and 10.9%, respectively, and of late Grade 1 and 2 GU toxicity were 3.1 and 1.6%, respectively. No acute or late gastrointestinal (GI) toxicity occurred. Transurethral resection of the prostate (TURP) was a risk factor that predicted a decline in urinary related QOL, and age made a difference to bowel-related QOL. For sexual QOL, castration status was a remarkable risk factor. An international prostate symptom score (IPSS) ≥8 increased the risk of Grade 1–2 acute GU toxicity 5.3-fold.

Conclusion

Patients with prostate cancer had favorable QOL after CIRT. IPSS ≥8 was a risk factor to acute GU toxicity, and TURP predicted a decline in urinary QOL. Age was related to bowel QOL, and castration status was associated with sexual QOL.

Trial registration

Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer, NCT02739659. Registered April 15, 2016.
Literature
1.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;2(66):115–32.CrossRef
2.
Karger CP, Peschke P. RBE and related modeling in carbon-ion therapy. Phys Med Biol. 2017;63(1):01TR2.CrossRef
3.
Strigari L, Torriani F, Manganaro L, Inaniwa T, Dalmasso F, Cirio R, et al. Tumour control in ion beam radiotherapy with different ions in the presence of hypoxia: an oxygen enhancement ratio model based on the microdosimetric kinetic model. Phys Med Biol. 2018;63(6):065012.CrossRef
4.
Schiller KC, Habl G, Combs SE. Protons, photons, and the prostate - is there emerging evidence in the ongoing discussion on particle therapy for the treatment of prostate Cancer? Front Oncol. 2016;6:8.CrossRef
5.
Habl G, Uhl M, Katayama S, Kessel KA, Hatiboglu G, Hadaschik B, et al. Acute toxicity and quality of life in patients with prostate Cancer treated with protons or carbon ions in a prospective randomized phase II study the IPI trial. Int J Radiat Oncol Biol Phys. 2016;95(1):435–43.CrossRef
6.
Kasuya G, Ishikawa H, Tsuji H, Haruyama Y, Kobashi G, Ebner DK, et al. Cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy. Cancer Sci. 2017;108(12):2422–9.CrossRef
7.
Marvaso G, Jereczek-Fossa BA, Vischioni B, Ciardo D, Giandini T, Hasegawa A, et al. Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients. Tumori. 2017;103(3):314–8.CrossRef
8.
9.
10.
Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate Cancer index composite instrument for measuring health-related quality of life among prostate Cancer survivors. Urology. 2010;76(5):1245–50.CrossRef
11.
Gay HABH, O'Meara E, Bosch WR. Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy oncology group consensus panel atlas. Int J Radiat Oncol Biol Phys. 2012;83(3):e353–62.CrossRef
12.
13.
Choi EPH, Chin WY, Lam CLK, Wan EYF. The responsiveness of the international prostate symptom score, incontinence impact questionnaire 7 and depression, anxiety and stress scale 21 in patients with lower urinary tract symptoms. J Adv Nurs. 2015;71(8):1857–70.CrossRef
14.
Bayoud Y, de la Taille A, Ouzzane A, Ploussard G, Allory Y, Yiou R, et al. International prostate symptom score is a predictive factor of lower urinary tract symptoms after radical prostatectomy. Int J Urol. 2015;22(3):283–7.CrossRef
15.
Marshall LM, Lapidus JA, Wiedrick J, Barrett-Connor E, Bauer DC, Orwoll ES, et al. Lower urinary tract symptoms and risk of nonspine fractures among older community dwelling U.S. men. J Urol. 2016;196(1):166–72.CrossRef
16.
17.
Lam WWT, Tse MA, Ng CNL, Chung EKM, Fielding R. Psychometric assessment of the Chinese version of the abbreviated expanded prostate Cancer index composite (EPIC-26) and the clinical practice version (EPIC-CP) in Chinese men with prostate Cancer. J Pain Symptom Manag. 2017;53(6):1085–90.CrossRef
18.
19.
Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, et al. Minimally important difference for the expanded prostate Cancer index composite short form. Urology. 2015;85(1):101–5.CrossRef
20.
Roberson IJD, McDonald AM, Baden CJ, Lin CP, Jacob R, Burnett IOL. Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies. World J Gastroenterol. 2016;22(10):3006–14.CrossRef
21.
Wang J, Song Y, Liu X, Jin J, Wang W, Yu Z, et al. Comparison of outcome and toxicity of postoperative intensity-modulated radiation therapy with two-dimensional radiotherapy in patients with soft tissue sarcoma of extremities and trunk. Cancer Med. 2019;8(3):902–9.CrossRef
22.
Kurian CJ, Leader AE, Thong MSY, Keith SW, Zeigler-Johnson CM. Examining relationships between age at diagnosis and health-related quality of life outcomes in prostate cancer survivors. BMC Public Health. 2018;18(1):1060–9.CrossRef
23.
24.
Ishikawa H, Katoh H, Kaminuma T, Kawamura H, Ito K, Matsui H, et al. Carbon-ion radiotherapy for prostate Cancer: analysis of morbidities and change in health-related quality of life. Anticancer Res. 2015;35(10):55–9.
25.
Ishikawa H, Tsuji H, Kamada T, Hirasawa N, Yanagi T, Mizoe J-E, et al. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate Cancer. Int J Radiat Oncol Biol Phys. 2008;72(1):78–84.CrossRef
26.
Nomiya T, Tsuji H, Maruyama K, Toyama S, Suzuki H, Akakura K, et al. Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks. Br J Cancer. 2014;110(10):2389–95.CrossRef
27.
Budäus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, et al. Functional outcomes and complications following radiation therapy for prostate Cancer: a critical analysis of the literature. Eur Urol. 2011;61(1):112–27.CrossRef
28.
Ishiyama H, Hirayama T, Jhaveri P, Satoh T, Paulino AC, Xu B, et al. Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy? A systematic review. Am J Clin Oncol. 2014;37(3):297–304.CrossRef
29.
Pinkawa M, Klotz J, Djukic V, Petz D, Holy R, Eble MJ. Transurethral resection of the prostate after radiotherapy for prostate cancer: impact on quality of life. Int J Urol. 2014;21(9):899–903.CrossRef
30.
Antonakopoulos GN, Hicks RM, Hamilton E, Berry RJ. Early and late morphological changes (including carcinoma of the urothelium) induced by irradiation of the rat urinary bladder. Br J Cancer. 1982;46(3):403–16.CrossRef
31.
Blank TO, Bellizzi KM. A gerontologic perspective on cancer and aging. Cancer. 2008;112(S11):2569–76.CrossRef
32.
Hamstra DA, Stenmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S, et al. Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(5):1246–53.CrossRef
33.
Huang GJ, Sadetsky N, Penson DF. Health related quality of life for men treated for localized prostate Cancer with long-term follow up. J Urol. 2010;183(6):2206–12.CrossRef
34.
Sevilla C, Maliski SL, Kwan L, Connor SE, Litwin MS. Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy. Prostate Cancer Prostatic Dis. 2012;15(3):237–43.CrossRef
35.
Donovan KA, Gonzalez BD, Nelson AM, Fishman MN, Zachariah B, Jacobsen PB. Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: a controlled comparison. Psycho-oncology. 2018;27(1):316–24.CrossRef
36.
Donovan KA, Walker LM, Wassersug RJ, Thompson LM, Robinson JW. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer. 2015;121(24):4286–99.CrossRef
37.
Lee TK, Poon DMC, Ng ACF, Ho T, Singh-Carlson S, Joffres M, et al. Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index composite. Asia-Pac J Clin Oncol. 2018;14:10–5.CrossRef
38.
Malik R, Jani AB, Liauw SL. External beam radiotherapy for prostate cancer: urinary outcomes for men with high international prostate symptom scores (IPSS). Int J Radiat Oncol Biol Phys. 2011;80(4):1080–6.CrossRef
39.
Metadata
Title
Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer
Authors
Yafang Zhang
Ping Li
Qi Yu
Shuang Wu
Xue Chen
Qing Zhang
Shen Fu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2019
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-019-1303-3

Other articles of this Issue 1/2019

Radiation Oncology 1/2019 Go to the issue

Research

Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy

Research

Comparative clinical evaluation of atlas and deep-learning-based auto-segmentation of organ structures in liver cancer

Research

Simulation of dosimetry impact of 4DCT uncertainty in 4D dose calculation for lung SBRT

Research

Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC

Research

Prospective intra/inter-observer evaluation of pre-brachytherapy cervical cancer tumor width measured in TRUS and MR imaging

Review

Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review